ERNA insider transaction filings
Ernexa Therapeutics Inc. — 26 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-01. Screen ERNA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 8.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Bristol James Arthur — Director | 1 | — | — | 2 |
| Cicala Peter — Director | 1 | — | — | 2 |
| Luther Sanjeev — President and CEO, Director | 1 | — | — | 1 |
| Polinsky David — Director | 1 | — | — | 1 |
| Ratner Elena — Director | 1 | — | — | 1 |
| Wexler William A. — Director | 1 | — | — | 1 |
Recent Form 4 filings — Ernexa Therapeutics Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-01 | 4 | Cicala Peter — Director | Grant/award (A): 5,943 (derivative) @ $0 · Grant/award (A): 5,083 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Bristol James Arthur — Director | Grant/award (A): 8,320 (derivative) @ $0 · Grant/award (A): 5,083 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Polinsky David — Director | Grant/award (A): 5,083 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Luther Sanjeev — President and CEO, Director | Grant/award (A): 118,848 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Ratner Elena — Director | Grant/award (A): 5,944 (derivative) @ $0 | EDGAR |
| 2026-09-01 | 4 | Wexler William A. — Director | Grant/award (A): 5,943 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Cherington Charles — 10% owner | Purchase (P): 4,000,000 @ $0.50 · Purchase (P): 4,000,000 (derivative) | EDGAR |
| 2025-07-07 | 4 | Gurrola Sandra M — Sr. VP of Finance | Option exercise (M): 30 · Option exercise (M): 30 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Cherington Charles — 10% owner | Purchase (P): 21,241,163 @ $0.10 | EDGAR |
| 2025-05-07 | 4/A | Cherington Charles — 10% owner | Purchase (P): 261,756 · Purchase (P): 4,768,783 · Purchase (P): 1,237,762 · Purchase (P): 5,420,823 · Purchase (P): 1,562,988 · Sale (S) · +4 more | EDGAR |
| 2025-04-04 | 4 | Cherington Charles — 10% owner | Purchase (P): 3,768,397 @ $0.10 | EDGAR |
| 2025-02-10 | 4 | Cicala Peter — Director | Grant/award (A): 51,485 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Luther Sanjeev — President & CEO, Director | Grant/award (A): 1,123,350 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Wexler William A. — Director | Grant/award (A): 124,533 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Bristol James Arthur — Director | Grant/award (A): 72,074 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Gurrola Sandra M — Sr. VP of Finance | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-01-14 | 4 | Ratner Elena — Director | Grant/award (A): 140,078 (derivative) @ $0 | EDGAR |
| 2024-11-05 | 4 | Cherington Charles — 10% owner | Purchase (P): 261,756 · Purchase (P): 4,768,783 · Purchase (P): 1,237,762 · Purchase (P): 5,420,823 · Purchase (P): 1,562,988 · Conversion (C): 2,819,546 @ $0.50 · +11 more | EDGAR |
| 2024-06-25 | 4 | Gurrola Sandra M — Sr. VP of Finance | Option exercise (M): 437 · Tax withholding (F): 180 @ $1.94 · Option exercise (M): 437 (derivative) @ $0 | EDGAR |
| 2024-04-29 | 4 | Cicala Peter — Director | Grant/award (A): 88,946 (derivative) @ $0 | EDGAR |
| 2024-04-29 | 4 | Bristol James Arthur — Director | Grant/award (A): 124,525 (derivative) @ $0 | EDGAR |
| 2024-04-29 | 4 | Gurrola Sandra M — Sr. VP of Finance | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Clarke Dorothy J — General Counsel, Director | Grant/award (A): 168,521 (derivative) @ $0 | EDGAR |
| 2024-01-03 | 4 | Luther Sanjeev — President and CEO, Director | Grant/award (A): 1,685,218 (derivative) @ $0 | EDGAR |
| 2023-12-20 | 4 | Cherington Charles — 10% owner | Purchase (P) @ $3,000,000 · Purchase (P): 3,125,976 (derivative) @ $0.12 · Code (H): 2,307,692 (derivative) · Purchase (P): 2,307,692 (derivative) · Code (H): 523,512 (derivative) · Purchase (P): 523,512 (derivative) | EDGAR |
| 2023-12-18 | 4 | Freebird Partners LP — 10% owner Freebird Investments LLC — 10% owner HUFF CURTIS W — 10% owner | Disposition to issuer (D): 424,928 (derivative) · Grant/award (A): 424,928 (derivative) · Disposition to issuer (D): 524,474 (derivative) · Grant/award (A): 524,474 (derivative) · Purchase (P): 520,996 (derivative) @ $1.92 · Purchase (P): 1,041,992 (derivative) | EDGAR |
Recent 8-K events — Ernexa Therapeutics Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-09-16 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-04 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-02-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ERNA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →